2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2225

COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Abstract Number: 1291

COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic
Abstract Number: 308

Cross-Cultural Adaptation, Validation and Reliability Of The Brazilian Version Of The Psoriatic Arthritis Screening Evaluation Tool
Abstract Number: 133

Cross-Sectional Neurocognitive Data Do Not Support a Transition From Fibrofog To Alzheimer’s Disease In Fibromyalgia Patients
Abstract Number: 1933

Crowdsourcing Using The Audience Response System To Solve Medical Problems: A Pilot Study
Abstract Number: 2638

Cryoglobulinemia Vasculitis With Or Without Associated Cryofibrinogenemia: A Different Phenotype?
Abstract Number: 2780

Cumulative Exposure To Elevated Inflammatory Markers Is Associated With Increased Burden Of Atherosclerosis In Psoriatic Arthritis Patients: A Cohort Study
Abstract Number: 952

CX3CR1 Deficiency Attenuates Imiquimod-Induced Psoriasis-Like Skin Inflammation By Predominant Infiltration Of M2 Macrophages
Abstract Number: 942

CXCL13 Is a Marker Of Joint Involvement In Early Rheumatoid Arthritis
Abstract Number: 1395

CXCL13 Is Elevated In Early and In Established Seropositive Rheumatoid Arthritis and Correlates With Rheumatoid Factor Levels
Abstract Number: 2404

CXCL13-Producing CD4 T-Cells In Rheumatoid Synovitis Are a Distinct Subset
Abstract Number: 1559

Cyclophosphamide and Rituximab Combination Treatment For Severe Systemic Lupus erythematosus is Effective and Well Tolerated
Abstract Number: 2070

Cytokine Profiles In Polymyositis and Dermatomyositis Complicated With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease Or Anti-Aminoacyl tRNA Synthetase Antibody-Associated Interstitial Lung Disease
Abstract Number: 775

Cytokine-Mediated Repression Of The Lncrna Hotair Enhances Intracellular Signaling and The Expression Of Adhesion Molecules In Synovial Fibroblasts
Abstract Number: 144

Cytokines, Oxidative Stress Markers and Brain-Derived Neurotrophic Factor In Fibromyalgia Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].